LEWISVILLE, Texas, Aug. 26, 2013 (GLOBE NEWSWIRE) -- As a pioneer in oligonucleotide synthesis, Bio-Synthesis, Inc. has been pursuing the development of new oligonucleotide based technologies that can provide compounds which have superior binding affinity and chemical/biological stability. As such, Bio-Synthesis is excited to begin collaborations for commercial applications using Bridged Nucleic Acids (BNA). These RNA analogues can be synthesized and spiked with DNA or RNA in order to modify the formation of nucleic acid helices. BNA is a cutting edge technology which allows clinical diagnostics and therapeutic fields to take advantage of this novel nucleic acid propelling research to new levels.
Help employers find you! Check out all the jobs and post your resume.
